T Cell Costimulation Blockade may Prevent Tumour Necrosis Factor alpha Inhibitor-Induced Palmoplantar Pustulosis

Autor:	Burkhard Möller, Gion Caliezi, Diana Dan, S Rodenhausen
Rok vydání:	2011
Předmět:	musculoskeletal diseases medicine.medical_specialty Palmoplantar pustulosis Exacerbation Side effect business.industry Abatacept Arthritis medicine.disease Dermatology Gastroenterology Discontinuation Blockade Etanercept Rheumatology Internal medicine Medicine business medicine.drug
Zdroj:	Aktuelle Rheumatologie. 38:55-58
ISSN:	1438-9940 0341-051X
Popis:	Palmoplantar pustulosis (PPP) is a known side effect of tumour necrosis factor alpha (TNF-α) blocking agents. In this patient with HLAB27-associated spondyloarthritis, PPP started 6 months after the first exposure to Etanercept and persisted for 15 months in spite of reduced dosing for 6 months, and after discontinuation of TNF blockade and intermittent administration of topical corticosteroids for 9 months. T cell costimulation blockade using recombinant CTLA4-Ig (Abatacept) was started 4 months after stopping Etanercept for the treatment of both the refractory psoriatic skin manifestation and the joint inflammation, which relapsed after cessation of anti-TNF treatment. Only the skin manifestation responded satisfactorily to Abatacept after a delay of 5 months, but under prophylactic continuation of this treatment, it was possible to re-expose the patient to Etanercept again, thereby achieving a prompt remission of arthritis, now for more than 2 years, without a new exacerbation of PPP.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::5266bfc3da17a1a94fe57566472e41dc https://doi.org/10.1055/s-0031-1283199 Zobrazit plný text záznamu